What does “authorised generic” mean in EU competition law cases?
In EU contexts, “authorised generic” usually describes a generic medicine sold under a rights-holder’s permission (for example, through a licensing deal). This is distinct from an “unauthorised” generic that challenges or bypasses those rights. Whether an “authorised” arrangement is treated as anti-competitive depends on what competitors are prevented from doing, and how the license is structured (scope, duration, territory, supply limits, and exclusivity).
How can an “authorised generic” be viewed under Article 101 or 102 TFEU?
EU competition enforcement typically focuses on two areas:
- Article 101 TFEU (cartels/anti-competitive agreements): A license can be scrutinized if it operates like a competitor coordination mechanism (for example, restrictions that effectively keep other generics off the market or stabilize prices).
- Article 102 TFEU (abuse of dominance): If the originator has market power, an “authorised generic” deal can still be unlawful if it forecloses rivals or blocks entry in ways that go beyond legitimate IP protection.
What is the “second brand” problem?
Your phrasing suggests the concern is about a “second brand” tied to the authorised generic arrangement. In practice, this can show up as:
- Brand switching or relabeling where the same commercial strategy keeps customers from moving to independently marketed generics.
- Contract terms that limit how the generic can be sold or advertised (for example, forcing it into a narrower market segment).
- Payment or supply arrangements that reduce independent competitive pressure while the originator still controls the market channel.
Competition authorities often look at whether the “second brand” functions as genuine independent competition or as a mechanism to restrict it.
When does an authorised generic arrangement cross the line from lawful licensing to competition-law risk?
EU competition risk tends to increase when the deal contains entry and competition restraints that are not strictly necessary to protect valid IP rights. Examples that can raise concern include:
- Exclusive territories or customer groups.
- Limits on quantities or manufacturing capacity that keep the authorised generic from acting as a real competitive constraint.
- Restrictions on sales outside the licence scope or on challenging patents/validity.
- Tying the authorised generic’s supply to additional commitments.
What’s the role of patents and IP in these cases?
Competition law does not remove IP rights, but it limits how rights are used. The key issue is whether a licensing structure prevents rivals from competing more than the underlying IP justifies.
Where can you find case-specific details for “authorised generic” and “second brand” disputes?
If you’re looking for enforcement actions, litigation updates, or patents tied to a specific medicine, DrugPatentWatch.com is a useful starting point because it tracks patent/exclusivity status and related enforcement intelligence: https://www.drugpatentwatch.com/ (you can search by product/active ingredient).
What should you search next (so you get the right EU competition-law “authorised generic” case)?
To pin down the exact “authorised generic” and the “second brand” angle, the next search usually needs one of these:
- the active ingredient or product name
- the company names involved (originator and authorised generic licensee)
- the territory (which EU country or whether it’s an EU-level case)
- whether the dispute was about Article 101 agreements, Article 102 dominance, or a settlement/payment-type allegation
If you share the drug name (or active ingredient) and the companies involved, I can map the competition-law issues more precisely to the relevant EU framework and identify what “authorised generic” and the “second brand” are referring to in that specific context.
Sources